Profile data is unavailable for this security.
About the company
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
- Revenue in IDR (TTM)30.94tn
- Net income in IDR2.87tn
- Incorporated1967
- Employees13.06k
- LocationKalbe Farma Tbk PTGedung KALBE Let.Jend Suprato Kav. 4JAKARTA PUSAT 10510IndonesiaIDN
- Phone+62 2 142873888
- Fax+62 214256326
- Websitehttp://www.kalbe.co.id
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | 23.19tn | -3.73tn | 68.52tn | 15.56k | -- | 4.45 | -- | 2.96 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| Humanwell Healthcare Group Co Ltd | 55.75tn | 4.42tn | 68.92tn | 17.68k | 15.48 | 1.74 | -- | 1.24 | 1.21 | 1.21 | 15.25 | 10.73 | 0.6833 | 3.80 | 2.77 | 1,395,473.00 | 7.21 | 6.20 | 13.29 | 12.72 | 45.02 | 42.82 | 10.55 | 9.84 | 1.20 | 31.56 | 0.3293 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Akeso Inc | 10.23tn | 4.59tn | 72.45tn | 2.78k | 15.28 | 6.63 | 15.37 | 7.08 | 2.61 | 2.61 | 5.82 | 6.01 | 0.6168 | 0.3749 | 15.98 | 1,754,662.00 | 26.47 | -11.59 | 31.40 | -13.87 | 96.96 | -- | 42.91 | -42.49 | 4.39 | 19.18 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| Kalbe Farma Tbk PT | 30.94tn | 2.87tn | 73.36tn | 13.06k | 25.19 | 3.23 | 20.07 | 2.37 | 62.13 | 62.13 | 669.90 | 483.87 | 1.08 | 2.73 | 5.82 | 2,360,620,000.00 | 10.18 | 12.50 | 12.92 | 15.48 | 37.40 | 41.21 | 9.41 | 11.26 | 2.70 | -- | 0.0283 | 50.53 | 5.24 | 7.64 | -18.20 | 2.40 | -3.00 | 3.58 |
| Rohto Pharmaceutical Co Ltd | 28.22tn | 3.22tn | 75.31tn | 7.18k | 22.63 | 2.83 | 22.01 | 2.67 | 135.21 | 135.21 | 1,183.69 | 1,079.72 | 0.8259 | 2.59 | 4.17 | -- | 9.57 | 8.54 | 13.02 | 11.79 | 58.07 | 58.59 | 11.59 | 10.30 | 1.93 | -- | 0.0408 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Hubei Jumpcan Pharmaceutical Co Ltd | 21.85tn | 6.76tn | 76.05tn | 5.23k | 11.20 | 2.35 | -- | 3.48 | 3.26 | 3.26 | 10.54 | 15.51 | 0.5504 | 3.66 | 4.60 | 1,848,716.00 | 17.05 | 16.23 | 22.52 | 20.88 | 79.76 | 82.64 | 30.98 | 24.42 | 3.01 | -- | 0.1275 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Holder | Shares | % Held |
|---|---|---|
| RBC Global Asset Management (UK) Ltd.as of 30 Apr 2024 | 927.96m | 1.98% |
| First Sentier Investors (Hong Kong) Ltd.as of 29 Feb 2024 | 812.40m | 1.73% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 732.89m | 1.56% |
| First Sentier Investors (UK) IM Ltd.as of 31 May 2024 | 691.52m | 1.48% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 644.42m | 1.38% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 549.02m | 1.17% |
| Invesco Advisers, Inc.as of 30 Apr 2024 | 477.24m | 1.02% |
| PT Schroder Investment Management Indonesiaas of 31 Dec 2023 | 324.21m | 0.69% |
| BlackRock Advisors (UK) Ltd.as of 06 Jun 2024 | 263.42m | 0.56% |
| MFS International Singapore Pte Ltd.as of 30 Apr 2024 | 224.71m | 0.48% |
